Cybrexa Regains Rights to CBX-12
February 06, 2024 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
May 25, 2023 17:01 ET
|
Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
April 12, 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB
February 01, 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
December 15, 2022 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
The Market Will Be Driven By Entry Of New Products In The Market And Increasing Number Of Therapies In Clinical Trials Says Kuick Research
September 09, 2022 05:44 ET
|
KuicK Research
Singapore, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report Findings: Global Peptide Therapeutics Market Opportunity > USD 75...
Global Peptide Drug Conjugate Antibody Market Forecast 2026
July 06, 2021 08:34 ET
|
KuicK Research
DELHI, India, July 06, 2021 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights: First FDA Approved Peptide Drug Conjugate: Pepaxto...
Global Peptide Drug Conjugate Market Opportunity 2026 US Europe Japan South Korea Sales Forecast 2026
April 17, 2021 05:09 ET
|
KuicK Research
DELHI, India, April 17, 2021 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights: First FDA Approved Peptide Drug Conjugate: Pepaxto...